Skip to main content

Table 1 Baseline patient and disease characteristics

From: Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Median age at inclusion (years)

66

[39–85]

Performance status

 0

39

37.9%

 1

46

44.7%

 2

11

10.7%

 3

2

1.9%

 NA

3

2.9%

BMI (kg/m2)

27

[18.3–56.5]

HER2 status

 Positive

9

8.7%

 Negative

90

87.4%

 NA

4

3.9%

Disease presentation at metastatic setting*

 De novo

53

51.4%

 Relapsed

50

48.6%

  Adjuvant treatment

   Chemotherapy

37

74.0%

   Hormonotherapy

44

88.0%

    Tamoxifen

34

77.3%

    AI

25

56.8%

  Median delay from end of adjuvant treatment to metastatic diagnostic (months)

57.5

[37–107]

Metastatic treatment before AI introduction

 Chemotherapy

  Yes

26

25.2%

  No

77

74.8%

 Endocrine therapy except AI

  Yes

13

12.6%

  No

90

87.4%

AI status at inclusion

 Initiation at inclusion

75

72.8%

 Already started without progression

28

27.2%

  Median delay since AI introduction (months)

9.9

[6.2–63.8]

Median follow-up (months)

25.3

[3–92]

  1. Data are presented as no. (%) unless indicated otherwise
  2. *Presentation of advanced disease is defined as de novo (advanced at first presentation) or relapsed (relapsed after previous presentation with early-stage cancer)